Navigation Links
Ampio Pharmaceuticals Awarded European Patent that Strengthens Intellectual Property Protection for its key drug Ampion™
Date:12/7/2011

GREENWOOD VILLAGE, Colo., Dec. 7, 2011 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced receipt of notification of the granting of a European patent with broad claims directed to compositions containing DA-DKP, a cyclic dipeptide diketopiperazine which is the active ingredient of Ampion™.  The patent also includes claims for these compositions that target clinical treatments for inflammation and inflammatory diseases and conditions, such as arthritis and allergies.

Dr. David Bar-Or, Ampio's Chief Scientific Officer, noted "This is an important, composition of matter patent that complements the already extensive and robust portfolio of worldwide issued patents for Ampion™. The mechanism of action of Ampion™, an innate human biological small molecular weight compound, is unique as it not only inhibits the early activation of memory T cells but also affects an upstream event in inflammation by tightening vascular permeability among other effects."

Dr. Vaughan Clift, Ampio's Chief Regulatory Officer further noted " We believe that multiple inflammatory conditions might benefit from this biological drug and the company is currently testing two such indications in clinical trials:

  • The Ampion™-In-Knee (AIK) clinical trial for the treatment of osteoarthritis of the knee being conducted in Australia.  This trial was recently expanded to include a direct comparison to steroids and vehicle control and is expected to conclude by the end of this year.
  • The IRB approved, randomized, vehicle-controlled, double-blinded study conducted at Centers for Allergy and Asthma in Denver, Colorado for the treatment of rhinitis.  This tria
    '/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Ampio Pharmaceuticals Announces Agreement to Acquire Key Drug Delivery Technology
2. Ampio Pharmaceuticals Expands Patent Portfolio of Drugs for Treating Inflammatory Diseases
3. Ampio Pharmaceuticals Announces Positive Results on Ampion™ Trial for Relief of Nasal Inflammation
4. Champions Oncology, Inc. Appoints Executive Vice President and Chief Financial Officer to Management Team and Corporate Office Relocation
5. Ampio Pharmaceuticals Announces a Proof of Concept Trial of Danazol in the Treatment of Allergic Rhinitis Supports Mechanism of Action of Optina™
6. Ampio Pharmaceuticals Receives Notice of Allowance of its Two Patent Applications on the Combination of Zertane™ with Erectile Dysfunction Drugs in Canada
7. Ampio Announces Positive Results From 12-Week Open Label Extension Study of Zertane™ in Patients With Premature Ejaculation.
8. Champions Oncology Reports Fiscal 2012 First Quarter Financial Results
9. Ampio Pharmaceuticals Executes License and Development Agreement with Daewoong Co. Ltd. to Commercialize Zertane™ in South Korea
10. Ampio Pharmaceuticals Announces Treatment of First Patient in Phase 1b Ampion-In -Knee (AIK) Trial for Osteoarthritis in Australia
11. Ampio Pharmaceuticals, Inc. Releases Results From Phase III Clinical Trial of Zertane™ for the Treatment of Premature Ejaculation (PE), the Most Prevalent Form of Male Sexual Dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014  IRIDEX Corporation (NASDAQ: IRIX ... quarter 2014 financial results after the market closes on ... the release, the Company will host a conference call ... Time on Thursday, July 31, 2014 ... business developments. Interested parties may access the ...
(Date:7/24/2014)... and MENLO PARK, Calif. , July 24, ... ("DelMar" "the company") announced today that the company,s board of ... December 31 to June 30. Accordingly, DelMar will file a ... Jeffrey Bacha , president and CEO of DelMar ... step in achieving our goal of obtaining a senior exchange ...
(Date:7/24/2014)...  Kinex Pharmaceuticals announced the receipt of an allowance ... for the commencement of a Phase I clinical study ... to be allowed by the US FDA in the ... orally active and highly selective inhibitor of Src tyrosine ... of p53, G2/M arrest of proliferating cell populations and ...
Breaking Medicine Technology:DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 3Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 3Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 4
... invivodata inc., the ... and services for global clinical research, today announced ... provide the EXAcerbations of Chronic pulmonary disease Tool ... is a Patient-Reported Outcome (PRO) measure for evaluating ...
... testing in humans watershed moment for unique malaria ... a move that highlights the strength of public-private ... company Sanaria Inc., with support from the PATH ... 1 clinical trial -- the first tests in ...
Cached Medicine Technology:invivodata Certified to Deliver EXACT in COPD Trials 2invivodata Certified to Deliver EXACT in COPD Trials 3Phase 1 Trial of Whole-Parasite Malaria Vaccine to Begin 2Phase 1 Trial of Whole-Parasite Malaria Vaccine to Begin 3Phase 1 Trial of Whole-Parasite Malaria Vaccine to Begin 4
(Date:7/24/2014)... (PRWEB) July 25, 2014 Voted one ... of the global clients, BellasDress focuses on providing its ... useful fashion information. Recently, the company has announced its ... in the new range is created according to the ... big discounts, up to 68% off. , As a ...
(Date:7/24/2014)... Triangle Park, NC (PRWEB) July 24, 2014 ... elderly, ethnic minorities, and low-income households are disproportionately ... and public food safety net in the United ... International. , Under Section 743 of the Consolidated ... U.S. Department of Agriculture's Food and Nutrition Service ...
(Date:7/24/2014)... Four Seasons Resort Maui at ... $3 million renovation of the famed Maile suite and ... just in time to welcome summer guests vacationing to ... from the internationally-acclaimed BraytonHughes Design Studios, San Francisco and ... and the largest in Hawaii—received a complete re-envisioning. No ...
(Date:7/24/2014)... Just as fitness and health professionals take ... financial and marketing strength to be important as well. ... next level by using the most powerful communication tools ... Call Tracking and SMS texting solutions . , ... are quickly become integral in marketing and communication methods ...
(Date:7/24/2014)... HealthDay Reporter THURSDAY, July 24, ... may be dead wrong, according to a small study that asked ... with 33 boys between the ages of 14 and 16, researchers ... for the closeness and trust. Very few boasted about sexual conquests ... with a girl. "In our culture, we have lots of ...
Breaking Medicine News(10 mins):Health News:BellasDress Helps Brides Get High End Wedding Dresses for Their Romantic Weddings 2Health News:Report: Vulnerable Populations Disproportionately Affected by Food Security, Despite Public Programs 2Health News:Report: Vulnerable Populations Disproportionately Affected by Food Security, Despite Public Programs 3Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 2Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 3Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 4Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 5Health News:Pump Up Your Gym’s Marketing Muscles with Mobile Marketing: CallFire's Health & Fitness Webinar Week – July 28th to August 1st 2Health News:Pump Up Your Gym’s Marketing Muscles with Mobile Marketing: CallFire's Health & Fitness Webinar Week – July 28th to August 1st 3Health News:Teenage Boys Want Intimacy, Not Just Sex, Survey Finds 2Health News:Teenage Boys Want Intimacy, Not Just Sex, Survey Finds 3
... Buffalo announced today a $10 million gift from Jeremy M. ... Institute, which will support research and clinical collaboration on the ... ... D. Jacobs, M.D., a world-renowned medical pioneer and the late ...
... 13 Elekta, a world-class leader in,advanced ... virtual patient clinic, enabling clinicians, patients and,the ... themselves with,Elekta,s products* and solutions and how ... clinic, available via http://www.elekta.com/evc , ...
... HILL, N.C., June 13 Long and costly ... to,maximize limited staff and resources to the development ... companies are integrating,commercial insights earlier and earlier into ... and target promising compounds, reduce development cycle,time, focus ...
... in diet and other factors , , FRIDAY, June 13 (HealthDay ... advice to people at high risk of heart disease effectively ... cholesterol and smoking. , "The results we see are very ... Dr. David Wood, a cardiology professor at Imperial College in ...
... Friday 13 June 2008: Rheumatoid arthritis (RA), ... should undergo compulsory cardiovascular (CV) risk management and ... the increased CV risk in inflammatory rheumatic disease ... Management in RA, recommended today at EULAR 2008, ...
... WASHINGTON, June 13 A new "hospital report,card" ... the Department,s,health care system high marks, with VA ... accepted by the health,care industry., "This report ... care VA,provides to our veterans," said Dr. James ...
Cached Medicine News:Health News:$10 million gift will retain and recruit world-class researchers to University at Buffalo 2Health News:$10 million gift will retain and recruit world-class researchers to University at Buffalo 3Health News:$10 million gift will retain and recruit world-class researchers to University at Buffalo 4Health News:Elekta Launches Web-based Virtual Clinic, Offers Better Understanding of Radiotherapy Solutions for the Treatment of Cancer 2Health News:Bio-Pharma Launch Value Maximized Through New Product Commercialization Excellence 2Health News:Lifestyle Counseling Reduces Heart Risk 2Health News:Lifestyle Counseling Reduces Heart Risk 3Health News:CV risk management should be mandatory in RA and other types of inflammatory rheumatic disease 2Health News:CV risk management should be mandatory in RA and other types of inflammatory rheumatic disease 3Health News:Health Care 'Report Card' Gives VA High Marks 2
... are individually adjusted for perfect focus where ... on paper. This, along with Keeler's wide ... that whatever the patient's pupil size, you ... of view. Lithium-ion technology provides a longer ...
... 200 ophthalmoscope, the world's ... ophthalmoscope. Heine's aspherical optical ... along with innovative design ... the Beta 200 the ...
... The Heine Beta 200S is ... with a combination of patented ... and a range of corrective ... dpt. in single diopter steps. ...
... The ophthalmoscope with superior aspherical optics. The ... means of the aspherical optical system avoids ... 200 allows you to view the whole ... even with a small pupil. Conventional ophthalmoscopes ...
Medicine Products: